{"id":5030,"date":"2025-02-20T11:03:44","date_gmt":"2025-02-20T02:03:44","guid":{"rendered":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/?page_id=5030"},"modified":"2026-07-30T13:10:54","modified_gmt":"2026-07-30T04:10:54","slug":"research","status":"publish","type":"page","link":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/research\/","title":{"rendered":"\u7814\u7a76"},"content":{"rendered":"\n
<\/span>
\n
<\/div><\/div>\n\n\n\n
\n
\n
\"\u7814\u7a76\u3078\u306e\u53d6\u308a\u7d44\u307f\u306e\u88c5\u98fe\"<\/figure>\n<\/div>\n\n\n\n
\n

RESEARCH SUPPORT<\/strong><\/p>\n\n\n\n

\u85ac\u5b66\u7814\u7a76\u3092\u3001\u30c7\u30fc\u30bf\u306e\u529b\u3067\u652f\u3048\u308b\u3002<\/h2>\n\n\n\n

\u660e\u6cbb\u85ac\u79d1\u5927\u5b66 \u85ac\u5b66\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u30bb\u30f3\u30bf\u30fc\u306f\u3001\u672c\u5b66\u306b\u304a\u3051\u308b\u85ac\u5b66\u7814\u7a76\u3092\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u306e\u5074\u9762\u304b\u3089\u652f\u63f4\u3059\u308b\u62e0\u70b9\u3067\u3059\u3002\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u89e3\u6790\u3001NDB\u3092\u6d3b\u7528\u3057\u305f\u7814\u7a76\u652f\u63f4\u3001\u5c02\u7528\u89e3\u6790\u74b0\u5883\u306e\u6574\u5099\u3001MOE\u3092\u6d3b\u7528\u3057\u305f\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u652f\u63f4\u3092\u901a\u3058\u3066\u3001\u85ac\u5264\u75ab\u5b66\u3001\u81e8\u5e8a\u75ab\u5b66\u3001\u533b\u7642\u7d4c\u6e08\u3001\u5275\u85ac\u7814\u7a76\u306a\u3069\u306e\u63a8\u9032\u3092\u652f\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\n

\u672c\u30da\u30fc\u30b8\u3067\u306f\u3001\u7814\u7a76\u306b\u95a2\u3059\u308b\u652f\u63f4\u4f53\u5236\u3068\u7814\u7a76\u5b9f\u7e3e\u3092\u7d39\u4ecb\u3057\u307e\u3059\u3002\u6559\u80b2\u652f\u63f4\u306b\u95a2\u3059\u308b\u53d6\u308a\u7d44\u307f\u306f\u6559\u80b2\u30da\u30fc\u30b8<\/a>\u3067\u7d39\u4ecb\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/span>
\n
<\/div><\/div>\n\n\n\n

ROLE<\/strong><\/p>\n\n\n\n

\u672c\u30bb\u30f3\u30bf\u30fc\u306e\u7814\u7a76\u652f\u63f4<\/h2>\n\n\n\n

\u672c\u5b66\u306b\u306f\u3001\u81e8\u5e8a\u85ac\u5b66\u3001\u533b\u7642\u3001\u5275\u85ac\u3001\u80b2\u85ac\u3001\u85ac\u5264\u75ab\u5b66\u3001\u533b\u7642\u7d4c\u6e08\u3001\u30d0\u30a4\u30aa\u30a4\u30f3\u30d5\u30a9\u30de\u30c6\u30a3\u30af\u30b9\u3001\u30b1\u30e2\u30a4\u30f3\u30d5\u30a9\u30de\u30c6\u30a3\u30af\u30b9\u306a\u3069\u3001\u591a\u69d8\u306a\u5c02\u9580\u9818\u57df\u306e\u7814\u7a76\u8005\u304c\u5728\u7c4d\u3057\u3066\u3044\u307e\u3059\u3002\u672c\u30bb\u30f3\u30bf\u30fc\u3067\u306f\u3001\u7814\u7a76\u8a08\u753b\u3001\u89e3\u6790\u8a2d\u8a08\u3001\u7d71\u8a08\u89e3\u6790\u3001\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u6d3b\u7528\u3001\u5206\u5b50\u8a2d\u8a08\u652f\u63f4\u306a\u3069\u3001\u7814\u7a76\u306e\u76ee\u7684\u306b\u5fdc\u3058\u305f\u652f\u63f4\u3092\u884c\u3044\u3001\u5b66\u5185\u5916\u306e\u7814\u7a76\u9023\u643a\u3092\u4fc3\u9032\u3057\u307e\u3059\u3002<\/p>\n\n\n\n

\n
\n
\n

NDB \/ RWD<\/strong><\/p>\n\n\n\n

NDB\u3092\u6d3b\u7528\u3057\u305f\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u7814\u7a76\u652f\u63f4<\/h3>\n\n\n\n

NDB\u3092\u306f\u3058\u3081\u3068\u3059\u308b\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u3092\u6d3b\u7528\u3057\u3001\u85ac\u5264\u306e\u4f7f\u7528\u5b9f\u614b\u3001\u5b89\u5168\u6027\u3001\u6709\u52b9\u6027\u3001\u533b\u7642\u8cbb\u3001\u533b\u7642\u653f\u7b56\u306a\u3069\u306b\u95a2\u3059\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

Secure Room<\/strong><\/p>\n\n\n\n

\u5c02\u7528\u89e3\u6790\u5ba4\u306b\u3088\u308b\u5b89\u5168\u306a\u7814\u7a76\u74b0\u5883<\/h3>\n\n\n\n

\u533b\u7642\u30fb\u85ac\u5b66\u30c7\u30fc\u30bf\u3092\u9069\u5207\u306b\u53d6\u308a\u6271\u3046\u305f\u3081\u3001\u5229\u7528\u30eb\u30fc\u30eb\u306b\u57fa\u3065\u3044\u305f\u5c02\u7528\u89e3\u6790\u74b0\u5883\u3092\u6574\u5099\u3057\u3001\u4fe1\u983c\u6027\u306e\u9ad8\u3044\u7814\u7a76\u3092\u652f\u3048\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

MOE<\/strong><\/p>\n\n\n\n

\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u7814\u7a76\u306e\u652f\u63f4<\/h3>\n\n\n\n

MOE\u3092\u6d3b\u7528\u3057\u3001\u5206\u5b50\u69cb\u9020\u306e\u53ef\u8996\u5316\u3001\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u30c9\u30c3\u30ad\u30f3\u30b0\u30b7\u30df\u30e5\u30ec\u30fc\u30b7\u30e7\u30f3\u306a\u3069\u3001\u5275\u85ac\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u306b\u95a2\u308f\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/span>
\n
<\/div><\/div>\n\n\n\n

RESEARCH FIELDS<\/strong><\/p>\n\n\n\n

\u652f\u63f4\u3059\u308b\u4e3b\u306a\u7814\u7a76\u9818\u57df<\/h2>\n\n\n\n

\u672c\u30bb\u30f3\u30bf\u30fc\u306f\u3001\u85ac\u5b66\u7814\u7a76\u306e\u3055\u307e\u3056\u307e\u306a\u9818\u57df\u306b\u5bfe\u3057\u3066\u3001\u30c7\u30fc\u30bf\u89e3\u6790\u30fb\u7814\u7a76\u8a2d\u8a08\u30fb\u89e3\u6790\u74b0\u5883\u306e\u9762\u304b\u3089\u652f\u63f4\u3092\u884c\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\n
\n
\n

\u85ac\u5264\u75ab\u5b66\u7814\u7a76<\/h3>\n\n\n\n

\u533b\u7642\u30c7\u30fc\u30bf\u3092\u7528\u3044\u3066\u3001\u85ac\u306e\u4f7f\u308f\u308c\u65b9\u3001\u5b89\u5168\u6027\u3001\u6709\u52b9\u6027\u306a\u3069\u3092\u691c\u8a0e\u3059\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u7814\u7a76<\/h3>\n\n\n\n

MOE\u306a\u3069\u306e\u89e3\u6790\u74b0\u5883\u3092\u6d3b\u7528\u3057\u3001\u85ac\u7269\u5019\u88dc\u5316\u5408\u7269\u306e\u63a2\u7d22\u3084\u5206\u5b50\u8a2d\u8a08\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

\u30d0\u30a4\u30aa\u30fb\u30b1\u30e2\u30a4\u30f3\u30d5\u30a9\u30de\u30c6\u30a3\u30af\u30b9<\/h3>\n\n\n\n

\u751f\u547d\u79d1\u5b66\u30c7\u30fc\u30bf\u3084\u5316\u5408\u7269\u30c7\u30fc\u30bf\u3092\u6d3b\u7528\u3057\u305f\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

\u81e8\u5e8a\u75ab\u5b66\u7814\u7a76<\/h3>\n\n\n\n

\u5b9f\u969b\u306e\u533b\u7642\u73fe\u5834\u3067\u5f97\u3089\u308c\u308b\u30c7\u30fc\u30bf\u3092\u6d3b\u7528\u3057\u3001\u75be\u60a3\u306e\u5b9f\u614b\u3084\u6cbb\u7642\u6210\u7e3e\u3092\u660e\u3089\u304b\u306b\u3059\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

\n
\n

\u533b\u7642\u7d4c\u6e08\u5b66\u7814\u7a76<\/h3>\n\n\n\n

\u533b\u7642\u8cbb\u3001\u85ac\u5264\u8cbb\u3001\u8cbb\u7528\u5bfe\u52b9\u679c\u306a\u3069\u3001\u533b\u7642\u3068\u7d4c\u6e08\u306b\u95a2\u308f\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

<\/span>
\n
<\/div><\/div>\n\n\n\n
\n
\n

DATABASE RESEARCH<\/strong><\/p>\n\n\n\n

\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u30fbRWD\u7814\u7a76\u652f\u63f4<\/h2>\n\n\n\n

\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\uff08Real World Data, RWD\uff09\u306f\u3001\u65e5\u5e38\u306e\u533b\u7642\u73fe\u5834\u304b\u3089\u5f97\u3089\u308c\u308b\u30c7\u30fc\u30bf\u306e\u7dcf\u79f0\u3067\u3059\u3002\u4fdd\u967a\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u3001\u96fb\u5b50\u30ab\u30eb\u30c6\u60c5\u5831\u3092\u542b\u3080\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u3001\u60a3\u8005\u30ec\u30b8\u30b9\u30c8\u30ea\u306a\u3069\u304c\u542b\u307e\u308c\u3001\u85ac\u5264\u75ab\u5b66\u7814\u7a76\u3001\u81e8\u5e8a\u75ab\u5b66\u7814\u7a76\u3001\u533b\u7642\u7d4c\u6e08\u5b66\u7814\u7a76\u306a\u3069\u306b\u6d3b\u7528\u3055\u308c\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

\u672c\u30bb\u30f3\u30bf\u30fc\u3067\u306f\u3001NDB\u3092\u542b\u3080\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u7814\u7a76\u306b\u5bfe\u5fdc\u3059\u308b\u305f\u3081\u3001\u7814\u7a76\u76ee\u7684\u306b\u5fdc\u3058\u305f\u89e3\u6790\u8a2d\u8a08\u3001\u7d71\u8a08\u89e3\u6790\u3001\u7d50\u679c\u306e\u89e3\u91c8\u3001\u7814\u7a76\u76f8\u8ac7\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div>\n\n\n\n

\n
\n
\n
\n
\n

\u4e3b\u306a\u652f\u63f4\u5185\u5bb9<\/h3>\n\n\n\n
    \n
  • \u7814\u7a76\u8ab2\u984c\u306e\u6574\u7406\u3068\u7814\u7a76\u8a08\u753b\u306e\u76f8\u8ac7<\/li>\n\n\n\n
  • \u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u7814\u7a76\u306b\u304a\u3051\u308b\u89e3\u6790\u8a2d\u8a08<\/li>\n\n\n\n
  • \u7d71\u8a08\u89e3\u6790\u30fb\u7d50\u679c\u89e3\u91c8\u306e\u652f\u63f4<\/li>\n\n\n\n
  • \u85ac\u5264\u75ab\u5b66\u30fb\u81e8\u5e8a\u75ab\u5b66\u30fb\u533b\u7642\u7d4c\u6e08\u7814\u7a76\u306e\u63a8\u9032\u652f\u63f4<\/li>\n\n\n\n
  • \u5c02\u7528\u89e3\u6790\u74b0\u5883\u306e\u5229\u7528\u652f\u63f4<\/li>\n<\/ul>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n
    <\/span>
    \n
    <\/div><\/div>\n\n\n\n
    <\/span>
    \n
    \n
    \n
    \"RWD\u3000\u30a4\u30e1\u30fc\u30b8\"<\/figure>\n<\/div>\n\n\n\n
    \n
    \n

    SECURE ANALYSIS ENVIRONMENT<\/strong><\/p>\n\n\n\n

    \u533b\u7642\u30fb\u85ac\u5b66\u30c7\u30fc\u30bf\u3092\u5b89\u5168\u306b\u6271\u3046\u5c02\u7528\u89e3\u6790\u74b0\u5883<\/h2>\n\n\n\n

    \u533b\u7642\u30fb\u85ac\u5b66\u30c7\u30fc\u30bf\u3092\u7528\u3044\u305f\u7814\u7a76\u3067\u306f\u3001\u30c7\u30fc\u30bf\u306e\u9069\u5207\u306a\u7ba1\u7406\u3068\u5229\u7528\u30eb\u30fc\u30eb\u306b\u57fa\u3065\u3044\u305f\u89e3\u6790\u74b0\u5883\u304c\u4e0d\u53ef\u6b20\u3067\u3059\u3002\u672c\u30bb\u30f3\u30bf\u30fc\u3067\u306f\u3001\u7814\u7a76\u8005\u304c\u5b89\u5168\u306b\u30c7\u30fc\u30bf\u89e3\u6790\u3092\u884c\u3048\u308b\u5c02\u7528\u89e3\u6790\u74b0\u5883\u3092\u6574\u5099\u3057\u3001\u8cea\u306e\u9ad8\u3044\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n\n\n\n

    \u3053\u3046\u3057\u305f\u7814\u7a76\u57fa\u76e4\u306f\u3001\u5b66\u5185\u7814\u7a76\u306e\u63a8\u9032\u306b\u52a0\u3048\u3001\u5b66\u5916\u6a5f\u95a2\u3068\u306e\u5171\u540c\u7814\u7a76\u3084\u3001\u85ac\u5b66\u5206\u91ce\u306b\u304a\u3051\u308b\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u6d3b\u7528\u306e\u767a\u5c55\u306b\u3082\u3064\u306a\u304c\u308a\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n<\/div><\/div><\/div>\n\n\n\n

    <\/span>
    \n
    <\/div><\/div>\n\n\n\n
    \n
    \n
    \"MOE\u3092\u6d3b\u7528\u3057\u305f\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u7814\u7a76\u652f\u63f4\"<\/figure>\n<\/div>\n\n\n\n
    \n

    MOE<\/strong><\/p>\n\n\n\n

    MOE\u3092\u6d3b\u7528\u3057\u305f\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u7814\u7a76\u652f\u63f4<\/h2>\n\n\n\n

    \u672c\u30bb\u30f3\u30bf\u30fc\u3067\u306f\u3001MOE\uff08Molecular Operating Environment\uff09\u3092\u6d3b\u7528\u3057\u3001\u5275\u85ac\u7814\u7a76\u3084\u5206\u5b50\u8a2d\u8a08\u306b\u95a2\u308f\u308b\u7814\u7a76\u3092\u652f\u63f4\u3057\u3066\u3044\u307e\u3059\u3002\u5206\u5b50\u69cb\u9020\u306e\u53ef\u8996\u5316\u3001\u30bf\u30f3\u30d1\u30af\u8cea\u3068\u85ac\u7269\u5019\u88dc\u5316\u5408\u7269\u306e\u76f8\u4e92\u4f5c\u7528\u89e3\u6790\u3001\u30c9\u30c3\u30ad\u30f3\u30b0\u30b7\u30df\u30e5\u30ec\u30fc\u30b7\u30e7\u30f3\u306a\u3069\u3092\u901a\u3058\u3066\u3001\u85ac\u5b66\u7814\u7a76\u306b\u304a\u3051\u308b\u5275\u85ac\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u306e\u6d3b\u7528\u3092\u63a8\u9032\u3057\u307e\u3059\u3002<\/p>\n\n\n\n

    \n
    \n
    \n

    \u69cb\u9020\u306e\u53ef\u8996\u5316<\/h3>\n\n\n\n

    \u5206\u5b50\u3084\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u7acb\u4f53\u69cb\u9020\u3092\u53ef\u8996\u5316\u3057\u3001\u7814\u7a76\u76ee\u7684\u306b\u5fdc\u3058\u305f\u7406\u89e3\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

    \n
    \n

    \u76f8\u4e92\u4f5c\u7528\u89e3\u6790<\/h3>\n\n\n\n

    \u85ac\u7269\u5019\u88dc\u5316\u5408\u7269\u3068\u6a19\u7684\u5206\u5b50\u306e\u76f8\u4e92\u4f5c\u7528\u3092\u89e3\u6790\u3057\u3001\u5275\u85ac\u7814\u7a76\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

    \n
    \n

    \u89e3\u6790\u76f8\u8ac7<\/h3>\n\n\n\n

    MOE\u306e\u6d3b\u7528\u65b9\u6cd5\u3084\u89e3\u6790\u65b9\u91dd\u306b\u3064\u3044\u3066\u3001\u7814\u7a76\u5185\u5bb9\u306b\u5fdc\u3058\u305f\u76f8\u8ac7\u3092\u53d7\u3051\u4ed8\u3051\u307e\u3059\u3002<\/p>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

    \n
    \n
    \n
    \n
    \n

    MOE\u3067\u5bfe\u5fdc\u53ef\u80fd\u306a\u89e3\u6790\u4f8b\u3092\u898b\u308b<\/strong><\/p>\n<\/span><\/div>\n\n\n\n

    \n

    MOE\u306f\u3001\u672c\u30bb\u30f3\u30bf\u30fc\u304c\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u7814\u7a76\u306e\u652f\u63f4\u306b\u7528\u3044\u308b\u30c4\u30fc\u30eb\u306e\u4e00\u3064\u3067\u3059\u3002\u5b9f\u969b\u306e\u89e3\u6790\u306f\u7814\u7a76\u5185\u5bb9\u3084\u30c7\u30fc\u30bf\u306b\u5fdc\u3058\u3066\u8a2d\u8a08\u3057\u3001\u7d71\u8a08\u89e3\u6790\u3084\u6a5f\u68b0\u5b66\u7fd2\u306a\u3069\u4ed6\u306e\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u624b\u6cd5\u3068\u7d44\u307f\u5408\u308f\u305b\u3066\u9032\u3081\u307e\u3059\u3002\u4ee5\u4e0b\u306f\u3001\u7814\u7a76\u76ee\u7684\u306b\u5fdc\u3058\u3066\u5bfe\u5fdc\u3067\u304d\u308b\u89e3\u6790\u306e\u4f8b\u3067\u3059\u3002<\/p>\n\n\n\n

      \n
    • \u5206\u5b50\u30e2\u30c7\u30ea\u30f3\u30b0\u30fb\u5206\u5b50\u8a2d\u8a08<\/strong>\uff1a\u5206\u5b50\u69cb\u9020\u306e\u4f5c\u6210\u30fb\u7de8\u96c6\u30fb\u6700\u9069\u5316\u3084\u3001\u30bf\u30f3\u30d1\u30af\u8cea\u30fb\u6838\u9178\u306a\u3069\u306e\u751f\u4f53\u5206\u5b50\u306e\u7acb\u4f53\u69cb\u9020\u306e\u78ba\u8a8d\u3092\u901a\u3058\u3066\u3001\u5275\u85ac\u7814\u7a76\u306e\u521d\u671f\u691c\u8a0e\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/li>\n\n\n\n
    • \u30bf\u30f3\u30d1\u30af\u8cea\u2013\u30ea\u30ac\u30f3\u30c9\u9593\u306e\u30c9\u30c3\u30ad\u30f3\u30b0<\/strong>\uff1a\u6a19\u7684\u30bf\u30f3\u30d1\u30af\u8cea\u3068\u85ac\u7269\u5019\u88dc\u5316\u5408\u7269\u306e\u7d50\u5408\u69d8\u5f0f\u3084\u30c9\u30c3\u30ad\u30f3\u30b0\u30b9\u30b3\u30a2\u3092\u8a55\u4fa1\u3057\u3001\u5019\u88dc\u5316\u5408\u7269\u306e\u7d5e\u308a\u8fbc\u307f\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/li>\n\n\n\n
    • \u30b1\u30e2\u30a4\u30f3\u30d5\u30a9\u30de\u30c6\u30a3\u30af\u30b9\u89e3\u6790<\/strong>\uff1a\u5316\u5408\u7269\u30c7\u30fc\u30bf\u306e\u7ba1\u7406\u30fb\u6574\u7406\u3084\u3001\u69cb\u9020\u6d3b\u6027\u76f8\u95a2\uff08QSAR\uff09\u306a\u3069\u3001\u5316\u5408\u7269\u30c7\u30fc\u30bf\u3092\u6d3b\u7528\u3057\u305f\u89e3\u6790\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/li>\n\n\n\n
    • \u30d0\u30fc\u30c1\u30e3\u30eb\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0<\/strong>\uff1a\u591a\u6570\u306e\u5316\u5408\u7269\u304b\u3089\u6709\u671b\u306a\u5019\u88dc\u3092\u52b9\u7387\u7684\u306b\u7d5e\u308a\u8fbc\u3080\u8a08\u7b97\u30b9\u30af\u30ea\u30fc\u30cb\u30f3\u30b0\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/li>\n\n\n\n
    • \u69cb\u9020\u30fb\u76f8\u4e92\u4f5c\u7528\u306e\u53ef\u8996\u5316<\/strong>\uff1a\u5206\u5b50\u3084\u30bf\u30f3\u30d1\u30af\u8cea\u306e\u7acb\u4f53\u69cb\u9020\u3084\u76f8\u4e92\u4f5c\u7528\u3092\u53ef\u8996\u5316\u3057\u3001\u7814\u7a76\u5185\u5bb9\u306e\u7406\u89e3\u3084\u8003\u5bdf\u3092\u652f\u63f4\u3057\u307e\u3059\u3002<\/li>\n\n\n\n
    • \u89e3\u6790\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u306e\u76f8\u8ac7<\/strong>\uff1a\u3069\u306e\u89e3\u6790\u3092\u3069\u306e\u9806\u5e8f\u3067\u884c\u3046\u304b\u3001\u89e3\u6790\u65b9\u91dd\u305d\u306e\u3082\u306e\u306b\u3064\u3044\u3066\u3082\u7814\u7a76\u5185\u5bb9\u306b\u5fdc\u3058\u3066\u76f8\u8ac7\u306b\u5bfe\u5fdc\u3057\u307e\u3059\u3002<\/li>\n<\/ul>\n\n\n\n

      \u203b \u3053\u3053\u3067\u6319\u3052\u305f\u89e3\u6790\u306f\u3001\u672c\u30bb\u30f3\u30bf\u30fc\u304c\u63d0\u4f9b\u3059\u308b\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u7814\u7a76\u652f\u63f4\u306e\u4e00\u4f8b\u3067\u3059\u3002MOE\u306e\u5229\u7528\u305d\u306e\u3082\u306e\u3092\u76ee\u7684\u3068\u3059\u308b\u306e\u3067\u306f\u306a\u304f\u3001\u7814\u7a76\u306e\u76ee\u7684\u306b\u5408\u308f\u305b\u3066\u6700\u9069\u306a\u624b\u6cd5\u3092\u4e00\u7dd2\u306b\u691c\u8a0e\u3057\u307e\u3059\u3002<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n

      <\/span>
      \n

      RESEARCH ACHIEVEMENTS<\/strong><\/p>\n\n\n\n

      \u7814\u7a76\u696d\u7e3e\u30fb\u6d3b\u52d5\u5b9f\u7e3e<\/h2>\n\n\n\n

      \u660e\u6cbb\u85ac\u79d1\u5927\u5b66\u3067\u306f\u3001\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u3001\u30ea\u30a2\u30eb\u30ef\u30fc\u30eb\u30c9\u30c7\u30fc\u30bf\u3001\u85ac\u5264\u75ab\u5b66\u3001\u533b\u7642\u7d4c\u6e08\u3001\u5275\u85ac\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u306a\u3069\u306b\u95a2\u3059\u308b\u7814\u7a76\u304c\u6d3b\u767a\u306b\u884c\u308f\u308c\u3066\u3044\u307e\u3059\u3002\u672c\u30bb\u30f3\u30bf\u30fc\u306f\u3001\u3053\u3046\u3057\u305f\u7814\u7a76\u3092\u652f\u3048\u308b\u57fa\u76e4\u3068\u3057\u3066\u3001\u89e3\u6790\u74b0\u5883\u306e\u6574\u5099\u3001\u7814\u7a76\u76f8\u8ac7\u3001\u30c7\u30fc\u30bf\u89e3\u6790\u652f\u63f4\u3092\u9032\u3081\u3066\u3044\u307e\u3059\u3002<\/p>\n\n\n\n

      \n

      2025\u5e74\u306b\u672c\u5b66\u304b\u3089\u767a\u8868\u3055\u308c\u305f\u3001\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u95a2\u9023\u306e\u7814\u7a76\u8ad6\u6587\u3092\u4e00\u89a7\u3067\u63b2\u8f09\u3057\u3066\u3044\u307e\u3059\u3002\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u30fbRWD\u7814\u7a76\u3001\u85ac\u5264\u75ab\u5b66\u3001\u533b\u7642\u7d4c\u6e08\u3001\u5b89\u5168\u6027\u76e3\u8996\uff08\u30d5\u30a1\u30fc\u30de\u30b3\u30d3\u30b8\u30e9\u30f3\u30b9\uff09\u3001\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u306a\u3069\u3001\u5e45\u5e83\u3044\u9818\u57df\u306e\u6210\u679c\u304c\u542b\u307e\u308c\u307e\u3059\u3002
      \u8ad6\u6587\u306f\u968f\u6642\u66f4\u65b0\u3057\u307e\u3059\u3002\u5b66\u4f1a\u767a\u8868\u30fb\u53d7\u8cde\u30fb\u5171\u540c\u7814\u7a76\u306a\u3069\u306e\u5b9f\u7e3e\u3082\u3001\u4eca\u5f8c\u3042\u308f\u305b\u3066\u63b2\u8f09\u3057\u3066\u3044\u304f\u4e88\u5b9a\u3067\u3059\u3002<\/p>\n<\/div><\/div>\n\n\n\n

      \u65b0\u7740\u7814\u7a76\u696d\u7e3e\uff082025\u5e74 \u8ad6\u6587\uff09<\/h3>\n\n\n\n

      2025\u5e74\u306b\u672c\u5b66\u304b\u3089\u767a\u8868\u3055\u308c\u305f\u3001\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u95a2\u9023\u306e\u7814\u7a76\u8ad6\u6587\u306e\u4e00\u89a7\u3067\u3059\u3002\u67a0\u5185\u3092\u4e0b\u306b\u30b9\u30af\u30ed\u30fc\u30eb\u3057\u3066\u3054\u89a7\u3044\u305f\u3060\u3051\u307e\u3059\u3002<\/p>\n\n\n\n

      <\/span>
      \n

      1. Realistically poseable mouse model for assessing exposures to magnetic field in the intermediate frequency band<\/h4>\n\n\n\n

      Wasoontarajaroen S, Ishiwata H, Chakarotha J, Ohtani S, Ushiyama A, Hattori K, Wada K, Ikehata M and Suzuki Y, IEEE Access, 13, 86528-86541 (2025)<\/p>\n\n\n\n

      2. Simultaneous detection of agricultural antibiotics via high-throughput LC-MS\/MS: residue survey in plant-based foods<\/h4>\n\n\n\n

      Nakajima T, Noguchi M, Hayashi H, Ohba Y, Yoshikawa S, Koike H and Tahara S, Food Addit Contam Part A, 42, 1380-1393 (2025)<\/p>\n\n\n\n

      3. Robust monitoring, risk assessment, and environmental impact of antibacterial residues in animal and fishery products collected in Tokyo from 2020 to 2024<\/h4>\n\n\n\n

      Koike H, Yoshikawa S, Nakajima T, Hayashi H, Ohba Y, Shiradoh H, Hayashi M, Nagano C, Matsushima Y, Kanda M and Tahara S, J Environ Sci Health B, 60, 447-455 (2025)<\/p>\n\n\n\n

      4. \u85ac\u7269\u6cbb\u7642\u4e2d\u306b\u8907\u6570\u65bd\u8a2d\u3092\u53d7\u8a3a\u3059\u308b\u75be\u60a3\u306e\u5b89\u5168\u6027\u60c5\u5831\u53ce\u96c6\u306b\u304a\u3051\u308b\u30ec\u30bb\u30d7\u30c8\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u306e\u9069\u7528\u53ef\u80fd\u6027\u306e\u691c\u8a0e<\/h4>\n\n\n\n

      \u5800\u5185\u6c99\u8389\u3001\u8d64\u6ca2 \u5b66\u3001\u85ac\u5264\u75ab\u5b66\u300130\u30011-11\uff082025\uff09<\/p>\n\n\n\n

      5. Trends of Strong and Weak Opioid Prescriptions in Japan: A Cross-Sectional Study Based on Open Data from the National Database and Hospital Claims Data from Fiscal Years 2015 to 2021<\/h4>\n\n\n\n

      Shoji T, Akazawa M, Nakagomi N, Kobayashi M, Kitta F, Inose R, Muraki Y, Iijima T and Suzuki T, Biol Pharm Bull, 48, 279-285 (2025)<\/p>\n\n\n\n

      6. Cost-effectiveness of systematic chemotherapy for metastatic pancreatic cancer: a retrospective study using Japanese clinical data<\/h4>\n\n\n\n

      Shinohara A, Takumoto Y, Tauchi J, Morishita K, Kawasaki T and Akazawa M, Sci Rep, 15, 267 (2025)<\/p>\n\n\n\n

      7. Delayed global standardization and prefectural disparities in systemic lupus erythematosus treatment in Japan: a nationwide study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan<\/h4>\n\n\n\n

      Yokogawa N, Sakai R, Matsushita M, Shimizu M, Inoue Y, Inoue E, Yamaji K, Mori M and Miyamae T, Mod Rheumatol, 35, 294-299 (2025)<\/p>\n\n\n\n

      8. Nationwide epidemiological survey of juvenile idiopathic arthritis during transition to young adulthood in Japan using the National Database of Designated Incurable Diseases of Japan<\/h4>\n\n\n\n

      Inoue Y, Sakai R, Inoue E, Mitsunaga K, Shimizu M, Sugihara T, Matsushita M, Yamaji K, Mori M, Shimojo N and Miyamae T, Mod Rheumatol, 35, 359-365 (2025)<\/p>\n\n\n\n

      9. Trends in syphilis treatments and the impact of intramuscular injectable Benzathine penicillin G in Japan: A descriptive study using administrative claims data from April 2016 to September 2023<\/h4>\n\n\n\n

      Shoji T, Akazawa M, Inoue O and Suzuki T, J Infect Chemother, 31, 102586 (2025)<\/p>\n\n\n\n

      10. Current status and challenges of health economic evaluations related to antimicrobial stewardship in Japan: A scoping review up to 2023<\/h4>\n\n\n\n

      Goto R, Inose R, Shoji T, Akazawa M and Muraki Y, J Infect Chemother, 31, 102657 (2025)<\/p>\n\n\n\n

      11. Persistence and adherence to sodium-glucose co-transporter 2 inhibitor monotherapy among patients with type 2 diabetes mellitus: a retrospective study based on a Japanese claims database<\/h4>\n\n\n\n

      Mukai J, Akazawa M, Yoshiyama Y and Kubota R, Diabetol Int, 16, 559-567 (2025)<\/p>\n\n\n\n

      12. Health economic evaluation of self-injection of biologics in patients with rheumatoid arthritis using a Japanese real-world web-based survey<\/h4>\n\n\n\n

      Takahata K, Maeda Y, Tanaka E, Sakai R and Akazawa M, BMC Health Serv Res, 25, 730 (2025)<\/p>\n\n\n\n

      13. Differences in asthma-related outcomes by anti-IL-5 biologics, omalizumab, and dupilumab based on blood eosinophil counts<\/h4>\n\n\n\n

      Kimura Y, Suzukawa M, Inoue N, Imai S, Horiguchi H, Akazawa M and Matsui H, Asian Pac J Allergy Immunol, 43, 290-299 (2025)<\/p>\n\n\n\n

      14. Vancomycin-associated acute kidney injury and its clinical and economic impact: a retrospective cohort study using two Japanese healthcare databases<\/h4>\n\n\n\n

      Murakami S, Ishiyama A, Otogawa S, Sakai R and Akazawa M, J Infect Chemother, 31, 102744 (2025)<\/p>\n\n\n\n

      15. Evaluating the potential of prevalent new user design as an alternative when new user design is impractical<\/h4>\n\n\n\n

      Koinuma T and Akazawa M, Pragmat Obs Res, 16, 155-168 (2025)<\/p>\n\n\n\n

      16. Evaluation of data quality and utility of the Japan Drug Information Institute in Pregnancy (JDIIP) consultation case database for pregnancy pharmacovigilance<\/h4>\n\n\n\n

      Matsuda S, Yakuwa N, Goto M, Akazawa M, Takahashi K, Anzai T, Koinuma S, Fujioka I, Miura Y, Ota M, Oka H, Nitani N, Tawaragi T and Murashima A, Drug Saf, 48, 1035-1046 (2025)<\/p>\n\n\n\n

      17. Electronic patient-reported outcome quality of life score in Japanese patients with pancreatic cancer on second-line chemotherapy: A multicenter observational study<\/h4>\n\n\n\n

      Takumoto Y, Ohba A, Terashima T, Ueno M, Ikezawa K, Okano N, Okusaka T, Morizane C, Ikeda M, Ozaka M, Narimatsu H, Akazawa M, Shiroiwa T and Furuse J, Cancer Med, 14, e71161 (2025)<\/p>\n\n\n\n

      18. Cost-effectiveness analysis of first-line chemotherapy for metastatic pancreatic cancer in Japan<\/h4>\n\n\n\n

      Sasahara Y, Takumoto Y, Murata T, Akazawa M and Narimatsu H, Cancer Med, 14, e71233 (2025)<\/p>\n\n\n\n

      19. Nationwide epidemiological survey of primary Sjogren's disease in Japan using the National Database of Designated Intractable Diseases<\/h4>\n\n\n\n

      Inoue Y, Sakai R, Inoue E, Mitsunaga K, Yamaji K, Mori M, Tomiita M, Shimojo N and Miyamae T, Mod Rheumatol, 35, 859-865 (2025)<\/p>\n\n\n\n

      20. Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: a cross-sectional study based on the National Database of Health Insurance Claims<\/h4>\n\n\n\n

      Matsushita M, Sakai R, Yokogawa N, Shimizu M, Inoue Y, Inoue E, Yamaji K, Mori M and Miyamae T, Mod Rheumatol, 35, 850-858 (2025)<\/p>\n\n\n\n

      21. Verification of unmet medical needs in patients with juvenile idiopathic arthritis in Japan<\/h4>\n\n\n\n

      Shimizu M, Inoue E, Sakai R, Inoue Y, Mitsunaga K, Sugihara T, Hirano T, Izawa K, Kishida D, Matsushita M, Mori M, Narazaki H, Nishikomori R, Sumitomo S, Tanaka T, Yamazaki S, Yamaji K, Yokogawa N, Yoshifuji H and Miyamae T, Mod Rheumatol, 35, 909-915 (2025)<\/p>\n\n\n\n

      22. Comparative clinical practice of juvenile idiopathic arthritis and rheumatoid arthritis in adolescents and young adults: A retrospective cohort study using Japanese health insurance claims data (2016-2020)<\/h4>\n\n\n\n

      Miyamae T, Sakai R, Inoue Y, Kato D, Inoue E, Hirano T, Izawa K, Kishida D, Matsushita M, Mitsunaga K, Mori M, Narazaki H, Nishikomori R, Shimizu M, Sugihara T, Sumitomo S, Tanaka T, Yamazaki S, Yamaji K, Yokogawa N, Yoshifuji H, Tanaka E and Harigai M, Mod Rheumatol, 35, 935-943 (2025)<\/p>\n\n\n\n

      23. Time trends in the prescription of sodium-glucose co-transporter-2 inhibitors based on a claims database in Japan from 2014 to 2022: expanded use in older adults, those with comorbidities, and those potentially initiating diabetes treatment<\/h4>\n\n\n\n

      Koinuma T, Yoshida M and Akazawa M, Diabetol Int, 17, 4 (2025)<\/p>\n\n\n\n

      24. Temporal trends in the prescription of biosimilars and the status of switching from original biologics to biosimilars at individual and institutional levels in Japan<\/h4>\n\n\n\n

      Matsumoto M, Kumazawa R, Ishii-Watanabe A, Horiguchi I, Mamiya H, Shibata H, Saito Y, Adomi M, Taniguchi Y, Komiyama J, Sakai R and Iwagami M, Ther Innov Regul Sci, 59, 1276-1287 (2025)<\/p>\n\n\n\n

      25. Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics<\/h4>\n\n\n\n

      Takahata K, Tanaka E, Sakai R and Akazawa M, Health Economics Review 15, 106 (2025)<\/p>\n\n\n\n

      26. MALDI-TOF MS analysis for detection of bovine coronavirus with tryptic peptides from viral proteins<\/h4>\n\n\n\n

      Hayashi K, Ohya K, Yoshinari T, Hirose S, Shimizu S, Morita Y, Ohnishi T, Watanabe M, Taharaguchi S, Mekata H, Taniguchi T and Hara-Kudo Y, J Microorganism Control, 29, 143-151 (2025)<\/p>\n\n\n\n

      27. Prediction of hyperkalemia occurrence in patients using co-trimoxazole: Clinical adjustment of a Markov model<\/h4>\n\n\n\n

      Watanabe F, Hirai T, Shiraishi C, Tasaka K, Iwamoto T and Hanada K, Int J Clin Pharmacol Ther, 63, 190-196 (2025)<\/p>\n\n\n\n

      28. Ultra-sensitive quantification of mid-regional proadrenomedullin in human plasma using micro-liquid chromatography coupled to quadrupole time-of-flight mass spectrometry<\/h4>\n\n\n\n

      Suzuki Y, Koyama T, Negami J, Toyama D, Oda A, Tanaka R, Iwao M, Tatsuta R, Ando T, Shin T, Itoh H and Ohno K, ACS Omega, 10, 24214-24223 (2025)<\/p>\n\n\n\n

      29. Ultra-sensitive quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in plasma using ultra-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry<\/h4>\n\n\n\n

      Negami J, Suzuki Y, Sato H, Toyama D, Oda A, Tanaka R, Ono H, Ando T, Shin T, Itoh H and Ohno K, J Clin Lab Anal, 39, e70077 (2025)<\/p>\n\n\n\n

      30. Investigation of the total anticholinergic load of reported anticholinergic drug-related adverse events using the Japanese Adverse Drug Event Report database: a retrospective pharmacovigilance study<\/h4>\n\n\n\n

      Kan Y, Doi M and Uesawa Y, Journal of Pharmaceutical Health Care and Sciences, 11, 1-8 (2025)<\/p>\n\n\n\n

      31. Disproportionality analysis of hepatotoxic and gastrointestinal adverse events associated with nintedanib using the Japanese Adverse Drug Event Report (JADER) database<\/h4>\n\n\n\n

      Fujiwara M, Ikesue H, Yamaoka K, Uchida M, Uesawa Y, Muroi N and Shimizu T, in vivo, 39, 396-403 (2025)<\/p>\n\n\n\n

      32. Comprehensive analysis of strong opioid side effects in palliative care using the SIDER database<\/h4>\n\n\n\n

      Hirai R, Kei M and Uesawa Y, Journal of Clinical Medicine, 14, 1410 (2025)<\/p>\n\n\n\n

      33. Development of a medication-related osteonecrosis of the jaw prediction model using the FDA Adverse Event Reporting System database and machine learning<\/h4>\n\n\n\n

      Toriumi S, Shimokawa K, Yamamoto M and Uesawa Y, Pharmaceuticals, 18, 423 (2025)<\/p>\n\n\n\n

      34. Investigation of nicotine-induced hiccups: Effects of administration route using the FDA adverse events reporting system<\/h4>\n\n\n\n

      Hosoya R, Ishii-Nozawa R, Terajima T, Kagaya H and Uesawa Y, Chem-Bio Informatics Journal, 25, 19-27 (2025)<\/p>\n\n\n\n

      35. Consensus modeling strategies for predicting transthyretin binding affinity from Tox24 challenge data<\/h4>\n\n\n\n

      Cirino T, Pinto L, Iwan M, Dougha A, Lu\u010di\u0107 B, Kraljevi\u0107 A, Navoyan Z, Tevosyan A, Yeghiazaryan H, Khondkaryan L, Abelyan N, Atoyan V, Babayan N, Iwashita Y, Kimura K, Komasaka T, Shishido K, Nakamura T, Asada M, Jain S, Zakharov AV, Wang H, Liu W, Chupakhin V and Uesawa Y, Chemical Research in Toxicology, 38, 1061-1071 (2025)<\/p>\n\n\n\n

      36. Comprehensive analysis of proteinuria and nephrotic syndrome using the Japanese adverse drug event reporting database<\/h4>\n\n\n\n

      Masago S, Yamaoka K, Uchida M, Uesawa Y, Yorifuji K and Shimizu T, in vivo, 39, 2073-2084 (2025)<\/p>\n\n\n\n

      37. Exploring adverse event associations of predicted PXR agonists using the FAERS database<\/h4>\n\n\n\n

      Yamada S and Uesawa Y, International Journal of Molecular Sciences, 26, 7630 (2025)<\/p>\n\n\n\n

      38. Comprehensive analysis of gastrointestinal injury induced by nonsteroidal anti-inflammatory drugs using data from FDA Adverse Event Reporting System database<\/h4>\n\n\n\n

      Kei M and Uesawa Y, Pharmaceuticals, 18, 1204 (2025)<\/p>\n\n\n\n

      39. Adverse events of antibody-drug conjugates: Comparative analysis of agents with a common payload using the adverse event spontaneous reporting database<\/h4>\n\n\n\n

      Yamaoka K, Masago S, Uchida M, Uesawa Y, Muroi N and Shimizu T, The Oncologist, 30, 1-12 (2025)<\/p>\n\n\n\n

      40. Steroid-induced thrombosis: A comprehensive analysis using the FAERS database<\/h4>\n\n\n\n

      Watanabe A and Uesawa Y, Pharmaceuticals, 18, 1463 (2025)<\/p>\n\n\n\n

      41. A comprehensive analysis of adverse events associated with HER2 inhibitors approved for breast cancer using the FDA adverse event report system (FAERS)<\/h4>\n\n\n\n

      Yajima A and Uesawa Y, Pharmaceuticals, 18, 1510 (2025)<\/p>\n\n\n\n

      42. Principal component analysis of antiseizure medication-induced hostility\/aggression and factor analysis of levetiracetam using the Food and Drug Administration Adverse Event Reporting System<\/h4>\n\n\n\n

      Hosoya R, Kitajima K, Sogawa K, Ikegami D, Terajima T, Kato H, Funada M, Kagaya H and Uesawa Y, Epilepsy Research, 218, 107626 (2025)<\/p>\n\n\n\n

      43. Trends in Kampo medicine usage as supportive care during anticancer drug treatment in Japanese patients: A nationwide cohort analysis from fiscal years 2015 to 2021<\/h4>\n\n\n\n

      Ohta H and Yasu T, Curr Oncol, 32, 100 (2025)<\/p>\n\n\n\n

      44. Incidence of hypothyroidism and thyroid function monitoring after immune checkpoint inhibitor therapy completion for lung cancer: A nationwide analysis of a Japanese claims database<\/h4>\n\n\n\n

      Ohta H, Tsugane H and Yasu T, Curr Oncol, 32, 558 (2025)<\/p>\n\n\n\n

      45. Gender differences in pharmacy professors in Japan and Korea<\/h4>\n\n\n\n

      Maeda H, Soh H, Hashimoto M, Han E and Ohno E, Lancet Reg Health West Pac, 54, 101469 (2025)<\/p>\n\n\n\n

      46. Prognostic value of HER2 discordance between primary and metastatic or recurrent breast cancer: a systematic review and meta-analysis<\/h4>\n\n\n\n

      Nakatani S, Hayashi T, Hosaka A and Maeda H, Crit Rev Oncol Hematol, 217, 105016 (2025)<\/p>\n\n\n\n

      47. Surrogate endpoints in pivotal clinical trials for drug approval in Japan compared to the United States<\/h4>\n\n\n\n

      Yamamoto Y, Kosaka H, Nojiri H and Maeda H, Clin Transl Sci, 18, e70413 (2025)<\/p>\n\n\n\n

      48. A cross-sectional study on the first-in-human trials of anticancer drugs in Japan and the United States and the probability of approval<\/h4>\n\n\n\n

      Mukaida A and Maeda H, Int J Clin Oncol, 30, 1946-1952 (2025)<\/p>\n\n\n\n

      49. Retrospective analysis of master protocols in tumor-agnostic drug development: Evaluation of application to single-agent therapies with ORR as the endpoint for approval of oncology drugs<\/h4>\n\n\n\n

      Yamamoto K, Takeda K and Maeda H, Clin Transl Sci, 18, e70313 (2025)<\/p>\n\n\n\n

      50. Characterization of Japanese risk management plans after 10 years of implementation: 2013-2023<\/h4>\n\n\n\n

      Sawada S, Asao K, Kobayashi R, Bosco J and Maeda H, Therapeutic Innovation & Regulatory Science, 1117-1128 (2025)<\/p>\n\n\n\n

      51. Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis<\/h4>\n\n\n\n

      Hirano S, Hanada K and Maeda H, Scientific Reports, 15, 19300 (2025)<\/p>\n\n\n\n

      52. Added therapeutic benefits of top-selling drugs in Japan: A cross-sectional study using health technology assessment<\/h4>\n\n\n\n

      Hakariya H, Ozaki A, Hashimoto T, Moriarty F, Maeda H and Tanimoto T, Clin Transl Sci, 18, e170243 (2025)<\/p>\n\n\n\n

      53. Dose optimization in oncology drug development: Risk factors for postmarketing requirements and commitments<\/h4>\n\n\n\n

      Kitagaki H, Takeda K, Murai K and Maeda H, Clin Pharmacol Ther, 118, 823-830 (2025)<\/p>\n\n\n\n

      54. Cross-sectional study and comparison between Japan and the United States on special regulatory pathways for expedited drug development and approval<\/h4>\n\n\n\n

      Kobayashi K, Inaba Y, Hashimoto M and Maeda H, Ther Innov Regul Sci, 59, 753-760 (2025)<\/p>\n\n\n\n

      55. \u88fd\u9020\u8ca9\u58f2\u5f8c\u8abf\u67fb\u53ca\u3073RWD\u6d3b\u7528\u306e\u73fe\u72b6\u3068\u8ab2\u984c<\/h4>\n\n\n\n

      \u524d\u7530\u82f1\u7d00\u3001JAPIC NEWS, 489, 4-6 (2025)<\/p>\n\n\n\n

      56. Population pharmacokinetic analysis in children with different diseases treated with mycophenolate mofetil-Integrated analysis of clinical trials and real-world clinical data<\/h4>\n\n\n\n

      Jumpei S, Akimasa Y, Miki A, Mayumi S, Kandai N, Kazumoto I and Hidefumi N, Eur J Pharm Sci, 204, 106970 (2025)<\/p>\n<\/div><\/div><\/div>\n\n\n<\/div><\/div><\/div>\n\n\n\n

      <\/span>
      \n
      <\/div><\/div>\n\n\n\n
      \n
      \n

      COLLABORATION<\/strong><\/p>\n\n\n\n

      \u5b66\u5185\u5916\u3068\u306e\u5171\u540c\u7814\u7a76\u652f\u63f4<\/h2>\n\n\n\n

      \u672c\u30bb\u30f3\u30bf\u30fc\u3067\u306f\u3001\u5b66\u5185\u7814\u7a76\u8005\u3092\u4e2d\u5fc3\u306b\u3001\u533b\u7642\u6a5f\u95a2\u3001\u4f01\u696d\u3001\u884c\u653f\u3001\u6559\u80b2\u6a5f\u95a2\u306a\u3069\u3068\u306e\u5171\u540c\u7814\u7a76\u3092\u30c7\u30fc\u30bf\u30b5\u30a4\u30a8\u30f3\u30b9\u306e\u5074\u9762\u304b\u3089\u652f\u63f4\u3057\u307e\u3059\u3002\u533b\u7642\u30c7\u30fc\u30bf\u30d9\u30fc\u30b9\u89e3\u6790\u3001\u85ac\u5264\u75ab\u5b66\u7814\u7a76\u3001\u5275\u85ac\u30fb\u5206\u5b50\u8a2d\u8a08\u652f\u63f4\u306a\u3069\u3092\u901a\u3058\u3066\u3001\u85ac\u5b66\u7814\u7a76\u306e\u767a\u5c55\u3068\u793e\u4f1a\u3078\u306e\u9084\u5143\u306b\u8ca2\u732e\u3057\u307e\u3059\u3002<\/p>\n<\/div>\n\n\n\n

      \n
      \n
      \n
      \n

      \u7814\u7a76\u652f\u63f4\u306b\u95a2\u3059\u308b\u3054\u76f8\u8ac7<\/h3>\n\n\n\n

      \u7814\u7a76\u652f\u63f4\u3001\u5171\u540c\u7814\u7a76\u3001\u89e3\u6790\u74b0\u5883\u306e\u5229\u7528\u306b\u95a2\u3059\u308b\u304a\u554f\u3044\u5408\u308f\u305b\u306f\u3001\u660e\u6cbb\u85ac\u79d1\u5927\u5b66 \u7dcf\u52d9\u8ab2\u307e\u3067\u304a\u9858\u3044\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n\n\n\n

      TEL\uff1a042-495-8611
      E\u30e1\u30fc\u30eb\uff1asomu@my-pharm.ac.jp<\/a><\/p>\n\n\n\n

      \u30e1\u30fc\u30eb\u3067\u554f\u3044\u5408\u308f\u305b\u308b<\/strong><\/span><\/div><\/a><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div><\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div>\n\n\n\n

      <\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":0,"parent":0,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_vk_print_noindex":"","sitemap_hide":"","vkExUnit_sitemap":"","_exclude_from_list_pages":"","vkexunit_cta_each_option":"","vkExUnit_childPageIndex":"","vkExUnit_pageList_ancestor":"","_lightning_design_setting":{"site_body_padding":"true"},"header_top_description":"","vk_page_header_image":0,"vk_page_header_image_sp":0,"vk_page_header_subtext":"RESEARCH","footnotes":""},"class_list":["post-5030","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/pages\/5030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/comments?post=5030"}],"version-history":[{"count":186,"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/pages\/5030\/revisions"}],"predecessor-version":[{"id":5646,"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/pages\/5030\/revisions\/5646"}],"wp:attachment":[{"href":"https:\/\/u-lab.my-pharm.ac.jp\/~dsc\/wp-json\/wp\/v2\/media?parent=5030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}